Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
-1.20% $1.502
America/New_York / 25 apr 2024 @ 11:29
FUNDAMENTALS | |
---|---|
MarketCap: | 3.94 mill |
EPS: | -5.01 |
P/E: | -0.300 |
Earnings Date: | Jun 26, 2024 |
SharesOutstanding: | 2.62 mill |
Avg Daily Volume: | 0.0083 mill |
RATING 2024-04-25 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.300 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.414 - 1.590 ( +/- 5.86%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Broenniman Edward G | Buy | 32 894 | Common Stock |
2024-04-16 | Rossetti Angela | Buy | 32 894 | Common Stock |
2024-04-16 | Shah Chetan | Buy | 32 894 | Common Stock |
2024-04-16 | Gikakis Nicolas | Buy | 32 894 | Common Stock |
2024-03-29 | Gikakis Nicolas | Sell | 1 954 | Common Stock |
INSIDER POWER |
---|
77.21 |
Last 96 transactions |
Buy: 2 829 634 | Sell: 209 502 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $1.502 (-1.20% ) |
Volume | 0.0002 mill |
Avg. Vol. | 0.0083 mill |
% of Avg. Vol | 2.93 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.